GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Hisse Senetlerindeki Sıralama
#3640
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Hisse Fiyatı
$27.73
Piyasa Değeri
$4.70B
Değişim (1 gün)
0.71%
Değişim (1 yıl)
-11.52%
Ülke
IN
Ticaret GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Kategori
Healthcare
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) için kazanç
Jun 2026 itibarıyla kazanç TTM: $159.96M
GlaxoSmithKline Pharmaceuticals Limited şirketinin en son finansal raporlarına göre, mevcut kazancı $159.96M'dir. 2024 yılında şirket $97.88M kazanç elde etti, bu 2023 yılındaki $101.78M kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
GlaxoSmithKline Pharmaceuticals Limited için kazanç geçmişi 2004 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $159.96M | 8.59% |
| 2025 | $147.31M | 50.49% |
| 2024 | $97.88M | -3.82% |
| 2023 | $101.78M | -0.83% |
| 2022 | $102.63M | 65.48% |
| 2021 | $62.02M | 52.81% |
| 2020 | $40.59M | -58.72% |
| 2019 | $98.31M | 18.54% |
| 2018 | $82.93M | 5.21% |
| 2017 | $78.83M | -9.71% |
| 2016 | $87.30M | -9.89% |
| 2015 | $96.88M | -0.90% |
| 2013 | $97.77M | -35.64% |
| 2012 | $151.90M | -13.05% |
| 2011 | $174.69M | -10.43% |
| 2010 | $195.02M | 19.11% |
| 2009 | $163.74M | 13.31% |
| 2008 | $144.51M | -9.37% |
| 2007 | $159.46M | 24.82% |
| 2006 | $127.75M | 17.87% |
| 2005 | $108.38M | 10.05% |
| 2004 | $98.49M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $33.60B | 20,902.13% |
US
|
|
| $17.74B | 10,988.20% |
US
|
|
| $8.70B | 5,338.14% |
US
|
|
| $5.95B | 3,618.36% |
US
|
|
| $21.39B | 13,270.79% |
CH
|
